Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Motorola Solutions Inc (MSI) Price & Performance

AbCellera Biologics IncTrade
Motorola Solutions IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Motorola Solutions Inc — how do they compare? AbCellera Biologics Inc trades at $8.95 (market cap $2.85B), while Motorola Solutions Inc trades at $466.86 (market cap $76.45B). The key difference: Motorola Solutions Inc is far larger — about 26.8× AbCellera Biologics Inc's market cap, and Motorola Solutions Inc pays a 1.05% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLMSI
Market Cap
$2.85B$76.45B
Sector
HealthTechnology
52-Week High
$9.76$490.30
52-Week Low
$2.78$363.83
Enterprise Value
$2.45B$85.36B
Dividend Yield
1.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

Motorola Solutions Inc

Motorola Solutions (MSI) trades at $467.55, down 1.38% on the day, yet maintains a strong bullish technical trend with moving averages signaling buy. The company reported robust Q2 2026 results, beating EPS estimates with $4.41 versus $3.85 expected, and raised full-year guidance amid record backlog of $15.6 billion. Revenue grew 13% year-over-year, driven by demand in public safety communications and software services. Valuation ratios remain elevated, with a P/E of 36.84 and P/S of 6.42, reflecting premium pricing for its growth trajectory.

Outlook is positive with analyst consensus price target of $533.80 implying 14% upside, supported by strong fundamentals and institutional accumulation. Key risks include execution challenges to meet raised guidance, high valuation sensitivity to earnings misses, and macroeconomic pressures on public sector spending. The stock's current level near pivot point resistance at $471 requires monitoring for breakout confirmation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Motorola Solutions Inc

Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.

Read more on MSI